PTGS1 compound heterozygosity impairs gene expression and platelet aggregation and is associated with severe bleeding complications

Eray Yagmur; Ralf Weiskirchen; Angelika Schede; Peter Bugert

doi:10.1160/TH13-02-0110

Thrombosis and Haemostasis, Inhaltsverzeichnis

Thromb Haemost 2013; 110(05): 1083-1085
DOI: 10.1160/TH13-02-0110

Letters to the Editor

Schattauer GmbH

PTGS1 compound heterozygosity impairs gene expression and platelet aggregation and is associated with severe bleeding complications

Autor*innen

Eray Yagmur

¹Laboratory Diagnostics Center, RWTH-University Hospital Aachen, Medical Care Center, Dr. Stein and colleagues, Mönchengladbach, Germany
Ralf Weiskirchen

²Institute of Clinical Chemistry and Pathobiochemistry, RWTH-University Hospital Aachen, Germany
Angelika Schede

¹Laboratory Diagnostics Center, RWTH-University Hospital Aachen, Medical Care Center, Dr. Stein and colleagues, Mönchengladbach, Germany

³Institute of Transfusion Medicine and Immunology, Heidelberg University, Medical Faculty Mannheim, Germany
Peter Bugert

³Institute of Transfusion Medicine and Immunology, Heidelberg University, Medical Faculty Mannheim, Germany

⁴German Red Cross Blood Service of Baden-Württemberg – Hessen gGmbH, Mannheim, Germany

Abstract

Volltext

Referenzen

References
1 Lee CR, Bottone FG Jr, Krahn JM. et al. Identification and functional characterization of polymorphisms in human cyclooxygenase-1 (PTGS1). Pharmacogenet Genomics 2007; 17: 145-160.
2 Lee C, North K, Bray M. et al. Cyclooxygenase polymorphisms and risk of cardiovascular events: The Atherosclerosis Risk in Communities (ARIC) Study. Clin Pharmacol Ther 2008; 83: 52-60.
3 Motovska Z, Kvasnicka J, Hajkova J. et al. Platelet gene polymorphisms and risk of bleeding in patients undergoing elective coronary angiography: a genetic substudy of the PRAGUE-8 trial. Atherosclerosis 2010; 212: 548-552.
4 Pereira C, Medeiros RM, Dinis-Ribeiro MJ. Cyclooxygenase polymorphisms in gastric and colorectal carcinogenesis: are conclusive results available?. Eur J Gastroenterol Hepatol 2009; 21: 76-91.
5 Warner TD, Mitchell JA. Cyclooxygenases: new forms, new inhibitors, and lessons from the clinic. FASEB J 2004; 18: 790-804.
6 Mani H, Wolf Z, Lindhoff-Last E. Progress in diagnostic evaluation of platelet function disorders. Hämostaseologie 2010; 30: 217-229.
7 Tóth O, Calatzis A, Penz S. et al. Multiple electrode aggregometry: a new device to measure platelet aggregation in whole blood. Thromb Haemost 2006; 96: 781-788.
8 Rolf N, Knoefler R, Bugert P. et al. Clinical and laboratory phenotypes associated with the Aspirin-like defect: a study in 17 unrelated families. Br J Haematol 2009; 144: 416-424.
9 Bugert P, Lese A, Meckies J. et al. Optimized sensitivity of allele-specific PCR for prenatal typing of human platelet alloantigen single nucleotide polymorphisms. Biotechniques 2003; 35: 170-174.
10 Diaz A, Reginato AM, Jimenez SA. Alternative splicing of human prostaglandin G/H synthase mRNA and evidence of differential regulation of the resulting transcripts by transforming growth factor β-1, interleukin 1-β, and tumor necrosis factor α. J Biol Chem 1992; 267: 10816-10822.
11 Rolf N, Knoefler R, Suttorp M. et al. Optimized procedure for platelet RNA profiling from blood samples with limited platelet numbers. Clin Chem 2005; 51: 1078-1080.